Bolloré Logistics Singapore inaugurated a new Asian cross-dock hub on November 9, 2018, shortly after partnership with a global pharmaceutical company.
Based in the USA, the pharmaceutical company is one of the leading figures in biopharma industry with focus on treatments for diabetes and oncology. The opening of an Asian cross-dock hub brings along a new distribution plan which will play a central role in the logistics management of products from the pharmaceutical plants in USA and Europe to the countries of its Asian markets.
Under the new supply chain model, the logistic flows from origins to destinations will be fully handled and monitored by the international network of Bolloré Logistics.
With a fully GDP1 and GMP2, compliant healthcare warehouse located in the FTZ3, Bolloré Logistics provides a solution that is capable of turnaround while ensuring products are stored in their optimal storage temperature environment. The switch from air to ocean solution aims to bring along better supply chain security, cost savings, end-to-end visibility, and lower carbon footprint.
“With the first shipment already in motion, we are extremely proud to announce that the cross-dock hub is officially in operations,” said Remi Lefevre, General Sales Manager at Bolloré Logistics Singapore.
Source: Bolloré Logistics
For your logistics and transportation management needs
Providing high frequency logistics and supply chain data and analysis for all those invested in the industry.